Volixibat is primarily used in the treatment of certain liver and gastrointestinal disorders. It functions as an inhibitor of the ileal bile acid transporter, which helps reduce the reabsorption of bile acids in the intestine. By doing so, it increases the excretion of bile acids, leading to a decrease in bile acid levels in the liver. This mechanism is particularly beneficial for patients with cholestatic liver diseases, such as primary biliary cholangitis, where bile acid accumulation can cause liver damage. Additionally, Volixibat has shown potential in managing pruritus, a common and distressing symptom associated with these conditions, by lowering systemic bile acid levels. Its application offers a targeted approach to alleviate symptoms and improve liver function in affected individuals.